S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Price, News & Analysis

$6.11
+0.04 (+0.66%)
(As of 02/23/2024 ET)
Today's Range
$5.93
$6.20
50-Day Range
$5.18
$7.29
52-Week Range
$1.61
$7.45
Volume
1.65 million shs
Average Volume
1.87 million shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.97

Autolus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
30.5% Upside
$7.97 Price Target
Short Interest
Healthy
1.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Autolus Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.01) to ($0.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

375th out of 939 stocks

Biological Products, Except Diagnostic Industry

58th out of 159 stocks


AUTL stock logo

About Autolus Therapeutics Stock (NASDAQ:AUTL)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

AUTL Stock Price History

AUTL Stock News Headlines

Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
AUTL Mar 2024 10.000 call
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update
AUTL Sep 2024 5.000 call
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up on Analyst Upgrade
Autolus Therapeutics’ Private Placement Raises Capital
Autolus Therapeutics Strikes Major Deal with BioNTech
Autolus Announces Pricing of Underwritten Offering
Autolus Upgrades Leadership And Faces CAR-T Approval
See More Headlines
Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
2/23/2024
Next Earnings (Estimated)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
399
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.97
High Stock Price Target
$12.00
Low Stock Price Target
$4.80
Potential Upside/Downside
+30.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-148,840,000.00
Pretax Margin
-3,180.50%

Debt

Sales & Book Value

Annual Sales
$6.36 million
Book Value
$1.73 per share

Miscellaneous

Free Float
129,235,000
Market Cap
$1.06 billion
Optionable
Optionable
Beta
1.92
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Christian Martin Itin Ph.D. (Age 60)
    CEO & Director
    Comp: $2.73M
  • Dr. Martin Pule M.D. (Age 52)
    MBBS, Founder, Senior VP & Chief Scientific Officer
  • Mr. Christopher Vann (Age 59)
    Senior VP & COO
  • Mr. David Brochu (Age 68)
    Senior VP & Chief Technical Officer
  • Mr. Brent Rice (Age 58)
    Senior VP, Chief Commercial Officer & Site Head of US
  • Dr. Edgar E. W. Braendle M.D. (Age 64)
    Ph.D., Senior VP & Chief Development Officer
  • Mr. Robert F. Dolski (Age 54)
    Chief Financial Officer
  • Ms. Olivia Manser
    Director of Investor Relations
  • Dr. Chris Williams (Age 44)
    Senior Vice President of Corporate Development
  • Mr. Alexander Swan
    Chief Human Resources Officer














AUTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AUTL shares.
View AUTL analyst ratings
or view top-rated stocks.

What is Autolus Therapeutics' stock price target for 2024?

8 analysts have issued twelve-month price objectives for Autolus Therapeutics' stock. Their AUTL share price targets range from $4.80 to $12.00. On average, they anticipate the company's stock price to reach $7.97 in the next year. This suggests a possible upside of 30.5% from the stock's current price.
View analysts price targets for AUTL
or view top-rated stocks among Wall Street analysts.

How have AUTL shares performed in 2024?

Autolus Therapeutics' stock was trading at $6.44 at the beginning of 2024. Since then, AUTL stock has decreased by 5.1% and is now trading at $6.11.
View the best growth stocks for 2024 here
.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 2,940,000 shares, an increase of 21.5% from the January 15th total of 2,420,000 shares. Based on an average trading volume of 1,380,000 shares, the days-to-cover ratio is presently 2.1 days.
View Autolus Therapeutics' Short Interest
.

When is Autolus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our AUTL earnings forecast
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.04. The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.25 million. During the same quarter in the prior year, the company posted ($0.72) EPS.

What ETF holds Autolus Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 44,025 shares of AUTL stock, representing 1.33% of its portfolio.

What other stocks do shareholders of Autolus Therapeutics own?
When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include TFG Asset Management GP Ltd (4.60%), Armistice Capital LLC (2.21%), Price T Rowe Associates Inc. MD (1.73%), Price T Rowe Associates Inc. MD (1.73%), Perpetual Ltd (1.19%) and Affinity Asset Advisors LLC (0.89%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUTL) was last updated on 2/23/2024 by MarketBeat.com Staff